Suven LifeSciences has seen a strong Q3 - albeit tempered from the Q2 this year - that will help the company end FY17 on a high note. The company declared a Q3 jump in net profit jump of 34.3% compared to the same quarter last year, with operating margins year on year helped by lower expenses and finance costs.

QoQ performance for the company saw net profits fall 8.6%, although for the overall nine month period Suven's incomes are up 9.98% and profits up 32.77% compared to the previous year. The company has secured 5 product patents in neurodegenerative treatments over the financial year, including Alzheimer's treatments.